Development in Practice – Special Issue: Endogenous Development (2014)

Development in Practice
Volume 24, Issue 5-6, 2014
http://www.tandfonline.com/toc/cdip20/current
Special Issue: Endogenous Development
[This special issue includes 14 articles around this theme with selected articles focused on the experience in Rwanda, Malawi, Nigeria, Ghana, and Somalia. Below are guest editor’s introduction and closing article]

Guest Editors’ introduction
Endogenous development: naïve romanticism or practical route to sustainable African development?
Chiku Malunga* & Susan H. Holcombe
DOI: 10.1080/09614524.2014.938616
pages 615-622
Abstract
Development theory and practice in developing countries are dominated by the power of Western ideas, worldviews, actors, tools, models, and frameworks. Consequently, the resulting development interventions may too rarely be locally rooted, locally driven, or resonant with local context. Another reality is that theories and practice from developing countries rarely travel to the Western agencies dominating development, undermining the possibility of a beneficial synergy that could be obtained from the best of the two worlds: West and developing countries. There are many reasons why the experience of locally driven development is not communicated back to global development actors, including but not limited to the marginal role of Southern voices in global fora. Perhaps the greatest unwelcome and unintended outcome is that by trying to create, or perhaps better said, “clone” development in developing countries in the image of Western “development”, development efforts defeat their own purpose through undermining their own relevance, legitimacy, and sustainability.

Endogenous development going forward: learning and action
Chiku Malunga* & Susan H. Holcombe
DOI: 10.1080/09614524.2014.938617
pages 777-781
Abstract
More than 50 years after independence Africa is yet to move from colonial to post-colonial identity – and to entitlement to determining its own destiny. Increasingly, however, African development thinkers and practitioners are questioning the dominance of externally driven, mostly Western models of development, which they believe have done little to date toward bringing about self-reliant sustainable development. We have observed successful patterns of endogenously led development in East Asia and Brazil. In Africa the papers included here suggest emerging new patterns of local leadership and of resurrecting and renewing cultural and traditional strengths to support modern development. Endogenous development, while a sometimes awkward term, is a concept increasingly informing practice.

Health of migrants in Europe

Editorial
The health of migrants and ethnic minorities in Europe: where do we go from here?
Oliver Razum1 and Karien Stronks2
Author Affiliations
1 Department of Epidemiology & International Public Health, School of Public Health, Bielefeld University, 33501 Bielefeld, Germany
2 Department of Public Health, Academic Medical Center, University of Amsterdam, 1100 DD Amsterdam, The Netherlands
Abstract
Between 0.4 (Slovakia) and 15.3% (Estonia) of the European population were born in a non-EU-27 (European Union-27) country,1 and this proportion is increasing in most member states. Given that migrants and ethnic minorities do not always have equal access to health services, their rights to health and health care are important public health topics. To improve the basis for further research and advocacy, these issues were discussed at the fifth EUPHA European Conference on Migrant and Minority Ethnic Health in Granada, Spain, in April 2014 (more details of the conference, including the programme and the volume of abstracts, can be found at http://www.eupha-migranthealthconference.com/).
Some of the lessons learned
The health of migrants and ethnic minorities should not be approached from a paternalistic perspective and with a focus only on deficits. On a population level, migrants (and also some ethnic minority groups) are comparatively healthier—especially with regard to non-communicable diseases such as cancer.2 Migrants and ethnic minorities are of course also exposed to health risks, such as limited accessibility to health care, …

Roma health is global ill health
Róza Ádány1,2,3
Author Affiliations
1 Department of Preventive Medicine, Faculty of Public Health, University of Debrecen, Debrecen, Hungary
2 MTA-DE Public Health Research Group of the Hungarian Academy of Sciences, University of Debrecen, Debrecen, Hungary
3 WHO Collaborating Centre on Vulnerability and Health, Faculty of Public Health, University of Debrecen, Debrecen, Hungary
Abstract
The accompanying paper by Kühlbrandt et al.1 begins to fill the void of quantitative data on access to health insurance coverage by Roma in Central Eastern European (CEE) countries. Survey data from 12 CEE countries clearly show that Roma, Europe’s largest ethnic minority, comprising up to 12% of the population of some of these countries, are significantly less likely to have health insurance than non-Roma in all countries except Slovakia and Serbia. The share of Roma without coverage reaches almost 30% in Bosnia–Herzegovina, over 40% in Bulgaria and Romania and 59.7% and 67.7% in Moldova and Albania, respectively. Throughout the region, Roma face poverty, poor access to education, high levels of unemployment and social exclusion. All of these might be expected to impact adversely on their health. Yet, …

The right of access to health care for undocumented migrants: a revision of comparative analysis in the European context
Amets Suess, Isabel Ruiz Pérez, Ainhoa Ruiz Azarola, and Joan Carles March Cerdà
Eur J Public Health (2014) 24 (5): 712-720 doi:10.1093/eurpub/cku036

Early Responders, Late Responders, and Non-responders: The Principal-Agent Problem in Board Oversight of Nonprofit CEOs

Human Service Organizations Management, Leadership & Governance
Volume 38, Issue 4, 2014
http://www.tandfonline.com/toc/wasw21/current#.U0sFzFcWNdc

Early Responders, Late Responders, and Non-responders: The Principal-Agent Problem in Board Oversight of Nonprofit CEOs
DOI: 10.1080/23303131.2014.916244
Amanda Rowe Tillotsona & John Tropmana*
pages 374-393
Abstract
Although scandals involving nonprofit executives occur frequently, these episodes follow different trajectories. In some cases, boards take immediate action to dismiss the executive; in others, boards delay action or attempt to rehabilitate the executive; in a final set, boards fail to act, and outside authorities and/or funders step in. In this last event, agencies close or lose their independence. Despite the prevalence of scandals and the differences in their outcomes, examinations of the factors that contribute to this variation are lacking. Here, we develop such a study, using principal agent theory to examine the way in which CEOs’ abilities to create informational asymmetries interact with characteristics of nonprofit boards to affect the outcome of these episodes. We use data obtained from case studies of nonprofit CEO malfeasance.
We hypothesize that specific characteristics of the nonprofit environment and of nonprofit boards interact with one another to exacerbate the principal agent problem by allowing nonprofit CEOs to create and exploit informational asymmetries. We find that board action is delayed or absent in instances where long-term CEOs are able to develop and exploit specific patterns of informational asymmetry. We find that specific difficulties with board monitoring in the nonprofit environment exacerbate these behaviors. We present recommendations to improve board performance.

Dynamics of Innovation in Nonprofit Organizations: The Pathways from Innovativeness to Innovation Outcome

Human Service Organizations Management, Leadership & Governance
Volume 38, Issue 4, 2014
http://www.tandfonline.com/toc/wasw21/current#.U0sFzFcWNdc

Dynamics of Innovation in Nonprofit Organizations: The Pathways from Innovativeness to Innovation Outcome
DOI:10.1080/23303131.2014.898005
Sangmi Choia* & Jae-Sung Choia
pages 360-373
Abstract
This study aims to examine the dynamics of innovation in human service nonprofits by investigating the pathways from innovativeness to innovation outcome through innovation input, process, and output. The findings from 258 community-based social service centers in South Korea suggest that innovativeness initiates innovation implementation and eventually contributes to innovation outcome. The study reveals that innovative culture may be the most important factor to facilitate innovation in human service nonprofits.

The Ebola Epidemic – A Global Health Emergency

JAMA
September 17, 2014, Vol 312, No. 11
http://jama.jamanetwork.com/issue.aspx

Viewpoint | September 17, 2014
The Ebola Epidemic – A Global Health Emergency
Lawrence O. Gostin, JD1; Daniel Lucey, MD, MPH2; Alexandra Phelan, LLM, BBiomedSc/LLB1
Author Affiliations
JAMA. 2014;312(11):1095-1096. doi:10.1001/jama.2014.11176.
Excerpt
On August 8, the World Health Organization (WHO) Director-General Margaret Chan declared the West Africa Ebola crisis a “public health emergency of international concern,”1 triggering powers under the 2005 International Health Regulations (IHR). The IHR requires countries to develop national preparedness capacities, including the duty to report internationally significant events, conduct surveillance, and exercise public health powers, while balancing human rights and international trade. Until last year, the director-general had declared only one such emergency—influenza AH1N1 (in 2009). Earlier this year, she declared poliomyelitis a public health emergency of international concern and now again for Ebola, signaling perhaps a new era of potential WHO leadership in global health security…

The Lancet Series – Midwifery [20 September 2014]

The Lancet
Sep 20, 2014 Volume 384 Number 9948 p1071 – 1158 e39 – 46
http://www.thelancet.com/journals/lancet/issue/current

Series – Midwifery
Midwifery and quality care: findings from a new evidence-informed framework for maternal and newborn care
Mary J Renfrew, Alison McFadden, Maria Helena Bastos, James Campbell, Andrew Amos Channon, Ngai Fen Cheung, Deborah Rachel Audebert Delage Silva, Soo Downe, Holly Powell Kennedy, Address Malata, Felicia McCormick, Laura Wick, Eugene Declercq
Preview |
In this first paper in a series of four papers on midwifery, we aimed to examine, comprehensively and systematically, the contribution midwifery can make to the quality of care of women and infants globally, and the role of midwives and others in providing midwifery care. Drawing on international definitions and current practice, we mapped the scope of midwifery. We then developed a framework for quality maternal and newborn care using a mixed-methods approach including synthesis of findings from systematic reviews of women’s views and experiences, effective practices, and maternal and newborn care providers.

The projected effect of scaling up midwifery
Caroline S E Homer, Ingrid K Friberg, Marcos Augusto Bastos Dias, Petra ten Hoope-Bender, Jane Sandall, Anna Maria Speciale, Linda A Bartlett
Preview |
We used the Lives Saved Tool (LiST) to estimate deaths averted if midwifery was scaled up in 78 countries classified into three tertiles using the Human Development Index (HDI). We selected interventions in LiST to encompass the scope of midwifery practice, including prepregnancy, antenatal, labour, birth, and post-partum care, and family planning. Modest (10%), substantial (25%), or universal (95%) scale-up scenarios from present baseline levels were all found to reduce maternal deaths, stillbirths, and neonatal deaths by 2025 in all countries tested.

New England Journal of Medicine: Ebola – 18 September 2014

New England Journal of Medicine
September 18, 2014 Vol. 371 No. 12
http://www.nejm.org/toc/nejm/medical-journal

Perspective
Face to Face with Ebola — An Emergency Care Center in Sierra Leone
A. Wolz
[Free Full Text]

Ebola — Underscoring the Global Disparities in Health Care Resources
Anthony S. Fauci, M.D.
N Engl J Med 2014; 371:1084-1086 September 18, 2014
DOI: 10.1056/NEJMp1409494
Audio Interview
Interview with Dr. Anthony Fauci on the current Ebola epidemic and the promise of candidate vaccines and therapies. (11:57) Listen

Studying “Secret Serums” — Toward Safe, Effective Ebola Treatments
J.L. Goodman
Jesse L. Goodman, M.D., M.P.H.
N Engl J Med 2014; 371:1086-1089 September 18, 2014 DOI: 10.1056/NEJMp1409817

Global Agricultural Land Resources – A High Resolution Suitability Evaluation and Its Perspectives until 2100 under Climate Change Conditio

PLoS One
[Accessed 20 September 2014]
http://www.plosone.org/

Research Article
Global Agricultural Land Resources – A High Resolution Suitability Evaluation and Its Perspectives until 2100 under Climate Change Conditions
Florian Zabel mail, Birgitta Putzenlechner, Wolfram Mauser
Published: September 17, 2014
DOI: 10.1371/journal.pone.0107522
Abstract
Changing natural conditions determine the land’s suitability for agriculture. The growing demand for food, feed, fiber and bioenergy increases pressure on land and causes trade-offs between different uses of land and ecosystem services. Accordingly, an inventory is required on the changing potentially suitable areas for agriculture under changing climate conditions. We applied a fuzzy logic approach to compute global agricultural suitability to grow the 16 most important food and energy crops according to the climatic, soil and topographic conditions at a spatial resolution of 30 arc seconds. We present our results for current climate conditions (1981–2010), considering today’s irrigated areas and separately investigate the suitability of densely forested as well as protected areas, in order to investigate their potentials for agriculture. The impact of climate change under SRES A1B conditions, as simulated by the global climate model ECHAM5, on agricultural suitability is shown by comparing the time-period 2071–2100 with 1981–2010. Our results show that climate change will expand suitable cropland by additionally 5.6 million km2, particularly in the Northern high latitudes (mainly in Canada, China and Russia). Most sensitive regions with decreasing suitability are found in the Global South, mainly in tropical regions, where also the suitability for multiple cropping decreases.

Coverage and Timing of Children’s Vaccination: An Evaluation of the Expanded Programme on Immunisation in The Gambia

PLoS One
[Accessed 20 September 2014]
http://www.plosone.org/

Coverage and Timing of Children’s Vaccination: An Evaluation of the Expanded Programme on Immunisation in The Gambia
Susana Scott, Aderonke Odutola, Grant Mackenzie, Tony Fulford, Muhammed O. Afolabi, Yamundow Lowe Jallow, Momodou Jasseh, David Jeffries, Bai Lamin Dondeh, Stephen R. C. Howie, Umberto D’Alessandro
Research Article | published 18 Sep 2014 | PLOS ONE 10.1371/journal.pone.0107280
Abstract
Objective
To evaluate the coverage and timeliness of the Expanded Programme on Immunisation (EPI) in The Gambia.
Methods
Vaccination data were obtained between January 2005 and December 2012 from the Farafenni Health and Demographic Surveillance System (FHDSS), the Basse Health and Demographic Surveillance System (BHDSS), the Kiang West Demographic surveillance system (KWDSS), a cluster survey in the more urban Western Health Region (WR) and a cross sectional study in four clinics in the semi-urban Greater Banjul area of WR. Kaplan-Meier survival function was used to estimate the proportion vaccinated by age and to assess timeliness to vaccination.
Findings
BCG vaccine uptake was over 95% in all regions. Coverage of DPT1 ranged from 93.2% in BHDSS to 99.8% in the WR. Coverage decreased with increasing number of DPT doses; DPT3 coverage ranged from 81.7% in BHDSS to 99.0% in WR. Measles vaccination coverage ranged from 83.3% in BHDSS to 97.0% in WR. DPT4 booster coverage was low and ranged from 43.9% in the WR to 82.8% in KWDSS. Across all regions, delaying on previous vaccinations increased the likelihood of being delayed for the subsequent vaccination.
Conclusions
The Gambia health system achieves high vaccine coverage in the first year of life. However, there continues to be a delay to vaccination which may impact on the introduction of new vaccines. Examples of effectively functioning EPI programmes such as The Gambia one may well be important models for other low income countries struggling to achieve high routine vaccination coverage.

WHO Essential Medicines Policies and Use in Developing and Transitional Countries: An Analysis of Reported Policy Implementation and Medicines Use Surveys

PLoS Medicine
(Accessed 20 September 2014)
http://www.plosmedicine.org/

WHO Essential Medicines Policies and Use in Developing and Transitional Countries: An Analysis of Reported Policy Implementation and Medicines Use Surveys
Kathleen Anne Holloway, David Henry
Research Article | published 16 Sep 2014 | PLOS Medicine 10.1371/journal.pmed.1001724
Abstract
Background
Suboptimal medicine use is a global public health problem. For 35 years the World Health Organization (WHO) has promoted essential medicines policies to improve quality use of medicines (QUM), but evidence of their effectiveness is lacking, and uptake by countries remains low. Our objective was to determine whether WHO essential medicines policies are associated with better QUM.
Methods and Findings
We compared results from independently conducted medicines use surveys in countries that did versus did not report implementation of WHO essential medicines policies. We extracted survey data on ten validated QUM indicators and 36 self-reported policy implementation variables from WHO databases for 2002–2008. We calculated the average difference (as percent) for the QUM indicators between countries reporting versus not reporting implementation of specific policies. Policies associated with positive effects were included in a regression of a composite QUM score on total numbers of implemented policies. Data were available for 56 countries. Twenty-seven policies were associated with better use of at least two percentage points. Eighteen policies were associated with significantly better use (unadjusted p<0.05), of which four were associated with positive differences of 10% or more: undergraduate training of doctors in standard treatment guidelines, undergraduate training of nurses in standard treatment guidelines, the ministry of health having a unit promoting rational use of medicines, and provision of essential medicines free at point of care to all patients. In regression analyses national wealth was positively associated with the composite QUM score and the number of policies reported as being implemented in that country. There was a positive correlation between the number of policies (out of the 27 policies with an effect size of 2% or more) that countries reported implementing and the composite QUM score (r = 0.39, 95% CI 0.14 to 0.59, p = 0.003). This correlation weakened but remained significant after inclusion of national wealth in multiple linear regression analyses. Multiple policies were more strongly associated with the QUM score in the 28 countries with gross national income per capita below the median value (US$2,333) (r = 0.43, 95% CI 0.06 to 0.69, p = 0.023) than in the 28 countries with values above the median (r = 0.22, 95% CI −0.15 to 0.56, p = 0.261). The main limitations of the study are the reliance on self-report of policy implementation and measures of medicine use from small surveys. While the data can be used to explore the association of essential medicines policies with medicine use, they cannot be used to compare or benchmark individual country performance.
Conclusions
WHO essential medicines policies are associated with improved QUM, particularly in low-income countries.
Editors’ Summary
Background
The widespread availability of effective medicines, particularly those used to treat infectious diseases, has been largely responsible for a doubling in the average global life expectancy over the past century. However, the suboptimal use (overuse and underuse) of medicines is an ongoing global public health problem. The unnecessary use of medicines (for example, the use of antibiotics for sore throats caused by viruses) needlessly consumes scarce resources and has undesirable effects such as encouraging the emergence of antibiotic resistance. Conversely, underuse deprives people of the undisputed benefits of many medicines. Since 1977, to help optimize medicine use, the World Health Organization (WHO) has advocated the concept of “essential medicines” and has developed policies to promote the quality use of medicines (QUM). Essential medicines are drugs that satisfy the priority needs of the human population and that should always be available to communities in adequate amounts of assured quality, in the appropriate dosage forms, and at an affordable price. Policies designed to promote QUM include recommendations that medicines should be free at the point of care and that all health care professionals should be educated about the WHO list of essential medicines (which is revised every two years) throughout their careers.
Why Was This Study Done?
Surveys of WHO member countries undertaken in 2003 and 2007 suggest that the implementation of WHO policies designed to promote QUM is patchy. Moreover, little is known about whether these policies are effective, particularly in middle- and low-income countries. For most of these countries, it is not known whether any of the policies affect validated QUM indicators such as the percentage of patients prescribed antibiotics (a lower percentage indicates better use of medicines) or the percentage of patients treated in compliance with national treatment guidelines (a higher percentage indicates better use of medicines). Here, the researchers analyze data from policy implementation questionnaires and medicine use surveys to determine whether implementation of WHO essential medicines policies is associated with improved QUM in low- and middle-income countries.
What Did the Researchers Do and Find?
The researchers extracted data on ten validated QUM indicators and on implementation of 36 policy variables from WHO databases for 2002–2008 and compared the average differences for the QUM indicators between low- and middle-income countries that did versus did not report implementation of specific WHO policies for QUM. Among 56 countries for which data were available, 27 policies were associated with improved QUM. Four policies were particularly effective, namely, doctors’ undergraduate training in standard treatment guidelines, nurses’ undergraduate training in standard treatment guidelines, the existence of a ministry of health department promoting the rational use of medicines, and the provision of essential medicines free to all patients at point of care. The researchers also analyzed correlations between how many of the 27 effective policies were implemented in a country and a composite QUM score. As national wealth increased, both the composite QUM score of a country and the reported number of policies implemented by the country increased. There was also a positive correlation between the numbers of policies that countries reported implementing and their composite QUM score. Finally, the implementation of multiple policies was more strongly associated with the composite QUM score in countries with a gross national income per capita below the average for the study countries than in countries with a gross national income above the average.
What Do These Findings Mean?
These findings show that between 2002 and 2008, the reported implementation of WHO essential medicines policies was associated with better QUM across low- and middle-income countries. These findings also reveal a positive correlation between the number of policies that countries report implementing and their QUM. Notably, this correlation was strongest in the countries with the lowest per capita national wealth levels, which underscores the importance of essential medicines policies in low-income countries. Because of the nature of the data available to the researchers, these findings do not show that the implementation of WHO policies actually causes improvements in QUM. Moreover, the age of the data, the reliance on self-report of policy implementation, and the small sample sizes of the medicine use surveys may all have introduced some inaccuracies into these findings. Nevertheless, overall, these findings suggest that WHO should continue to develop its medicine policies and to collect data on medicine use as part of its core functions.

Intimate Partner Violence and Reproductive Coercion: Global Barriers to Women’s Reproductive Control

PLoS Medicine
(Accessed 20 September 2014)
http://www.plosmedicine.org/

Intimate Partner Violence and Reproductive Coercion: Global Barriers to Women’s Reproductive Control
Jay G. Silverman, Anita Raj
Policy Forum | published 16 Sep 2014 | PLOS Medicine 10.1371/journal.pmed.1001723
Summary Points
:: Intimate partner violence (IPV) is a major contributor to poor reproductive outcomes (e.g., adolescent and unintended pregnancy) among women and girls globally.
:: To improve reproductive health, it is necessary that service provision goes beyond identification of women and girls affected by IPV to include identification of specific behaviors that reduce women and girls’ control over their reproductive health, e.g., reproductive coercion, and assistance to reduce harm caused by these behaviors.
:: In order to assist women and girls to mitigate the risks to their reproductive health caused by IPV and reproductive coercion, access to female-controlled contraceptive methods must be improved.
:: In addition to assisting women and girls to improve their control over their reproductive health, reduction of IPV and reproductive coercion in the longer term requires ongoing and multiple-sector efforts to transform the social norms that maintain men’s entitlement to control of women’s and girls’ bodies and their reproduction.

Ebola vaccine: Little and late

Science
19 September 2014 vol 345, issue 6203, pages 1417-1536
http://www.sciencemag.org/current.dtl

Infectious Disease
Ebola vaccine: Little and late
Jon Cohen
With the Ebola epidemic in West Africa continuing to spiral out of control, it’s become painfully clear that the tried-and-true strategies to contain outbreaks in the past have failed here. This has spurred hopes that biomedical interventions like vaccines and treatments can help slow the spread and save lives. But the leading biomedical countermeasures, which still are experimental and have just recently gone into humans for the first time, are in short supply. Companies, with help from the U.S. government, are looking at ways to pull out all the stops and ramp up production; but even with an all-out effort and a green light from the early human trials, manufacturers have little hope of having enough doses to make a dent in this epidemic for at least 9 months.

Scientific Productivity on Research in Ethical Issues over the Past Half Century: A JoinPoint Regression Analysis

Tropical Medicine and Health
Vol. 42(2014) No. 3
https://www.jstage.jst.go.jp/browse/tmh/42/3/_contents

Scientific Productivity on Research in Ethical Issues over the Past Half Century: A JoinPoint Regression Analysis
Nguyen Phuoc Long, Nguyen Tien Huy, Nguyen Thi Huyen Trang, Nguyen Thien Luan, Nguyen Hoang Anh, Tran Diem Nghi, Mai Van Hieu, Kenji Hirayama, Juntra Karbwang
Released: September 10, 2014
[Advance Publication] Released: July 17, 2014
Abstract
BACKGROUND: Ethics is one of the main pillars in the development of science. We performed a JoinPoint regression analysis to analyze the trends of ethical issue research over the past half century. The question is whether ethical issues are neglected despite their importance in modern research.
METHOD: PubMed electronic library was used to retrieve publications of all fields and ethical issues. JoinPoint regression analysis was used to identify the significant time trends of publications of all fields and ethical issues, as well as the proportion of publications on ethical issues to all fields over the past half century. Annual percent changes (APC) were computed with their 95% confidence intervals, and a p-value < 0.05 was considered statistically significant.
RESULTS: We found that publications of ethical issues increased during the period of 1965–1996 but slightly fell in recent years (from 1996 to 2013). When comparing the absolute number of ethics related articles (APEI) to all publications of all fields (APAF) on PubMed, the results showed that the proportion of APEI to APAF statistically increased during the periods of 1965–1974, 1974–1986, and 1986–1993, with APCs of 11.0, 2.1, and 8.8, respectively. However, the trend has gradually dropped since 1993 and shown a marked decrease from 2002 to 2013 with an annual percent change of –7.4%.
CONCLUSIONS: Scientific productivity in ethical issues research on over the past half century rapidly increased during the first 30-year period but has recently been in decline. Since ethics is an important aspect of scientific research, we suggest that greater attention is needed in order to emphasize the role of ethics in modern research.

Coverage and acceptability of cholera vaccine among high-risk population of urban Dhaka, Banglade

Vaccine
Volume 32, Issue 43, Pages 5531-5768 (29 September 2014)
http://www.sciencedirect.com/science/journal/0264410X/32/42

Coverage and acceptability of cholera vaccine among high-risk population of urban Dhaka, Bangladesh
Original Research Article
Pages 5690-5695
Md. Jasim Uddin, Tasnuva Wahed, Nirod Chandra Saha, Sheikh Shah Tanvir Kaukab, Iqbal Ansary Khan, Ashraful Islam Khan, Amit Saha, Fahima Chowdhury, John David Clemens, Firdausi Qadri
Abstract
The oral cholera vaccine (Shanchol), along with other interventions, is a potential new measure to prevent or control cholera. A mass cholera-vaccination programme was launched in urban Dhaka, Bangladesh, during February–April 2011 targeting about 173,041 people who are at high risk of cholera. This cross-sectional, descriptive study assessed the coverage and acceptability of the vaccine. The study used a quantitative household survey and qualitative data-collection techniques comprising focus-group discussions, in-depth interviews, and observations for assessment. The findings revealed that 88% of the target population received the first dose of the vaccine, and 79% received the second dose. Absence of persons at home was a prominent cause of not administering the first (71%) and the second dose (67%). Thirty-three percent of the respondents (n = 9308) did not like the taste of the vaccine. Only 1.3% and 3% recipients of the first dose and the second dose of the vaccine respectively reported adverse effects within 28 days of vaccination, and the adverse effects included vomiting or vomiting tendency and diarrhoea. To improve the coverage of the cholera vaccine, exploration of effective solutions to reach the unvaccinated population is required. The vaccine may be more acceptable to the community through changing its taste.

Pharmaceutical Portfolio Management: Global Disease Burden and Corporate Performance Metrics

Value in Health
Volume 17, Issue 6, p661-756 September 2014
http://www.valueinhealthjournal.com/current

Pharmaceutical Portfolio Management: Global Disease Burden and Corporate Performance Metrics
Rutger Daems, Edith Maes, Maneesha Mehra, Benjamin Carroll, Adrian Thomas
p732–738
Abstract
Background
Biopharmaceutical companies face multiple external pressures. Shareholders demand a profitable company while governments, nongovernmental third parties, and the public at large expect a commitment to improving health in developed and, in particular, emerging economies. Current industry commercial models are inadequate for assessing opportunities in emerging economies where disease and market data are highly limited.
Objective
The purpose of this article was to define a conceptual framework and build an analytic decision-making tool to assess and enhance a company’s global portfolio while balancing its business needs with broader social expectations.
Methods
Through a case-study methodology, we explore the relationship between business and social parameters associated with pharmaceutical innovation in three distinct disease areas. The global burden of disease–based theoretical framework using disability-adjusted life-years provides an overview of the burden associated with particular diseases. The social return on investment is expressed as disability-adjusted life-years averted as a result of the particular pharmaceutical innovation. Simultaneously, the business return on investment captures the research and development costs and projects revenues in terms of a profitability index.
Conclusions
The proposed framework can assist companies as they strive to meet the medical needs of populations around the world for decades to come.

No place is safe: violence against and among children and youth in street situations in Uganda

Vulnerable Children and Youth Studies
An International Interdisciplinary Journal for Research, Policy and Care
Volume 9, Issue 4, 2014
http://www.tandfonline.com/toc/rvch20/current#.Uzg2bFcWNdc

No place is safe: violence against and among children and youth in street situations in Uganda
DOI:10.1080/17450128.2014.934750
Eddy J. Walakiraa*, Ismael Ddumba-Nyanzia, Saba Lishanb & Michael Baizermanc
pages 332-340
Abstract
This article explores street children’s exposure to and responses to violence based on data collected in 21 major towns in Uganda. Findings show that violence among Ugandan street children is endemic, perpetuated by both street children against each other and adults. Both male and female children suffer outright abuse from police, occasional strangers, and from each other. Boys were more frequently physically abused while girls were more frequently abused emotionally and sexually. The study recommends policy-oriented actions linked to addressing the variations in the vulnerability to violence among children on the basis of gender, age and other risk factors and targeting the change of attitudes and behavior among duty bearers in various settings, which result in violence against children on the street.

The Sentinel

Human Rights Action :: Humanitarian Response :: Health ::
Holistic Development :: Sustainable Resilience
__________________________________________________
Week ending 13 September 2014

This weekly digest is intended to aggregate and distill key content from a broad spectrum of practice domains and organization types including key agencies/IGOs, NGOs, governments, academic and research institutions, consortiums and collaborations, foundations, and commercial organizations. We also monitor a spectrum of peer-reviewed journals and general media channels. The Sentinel’s geographic scope is global/regional but selected country-level content is included. We recognize that this spectrum/scope yields an indicative and not an exhaustive product. Comments and suggestions should be directed to:

David R. Curry
Editor &
Founding Managing Director
GE2P2 – Center for Governance, Evidence, Ethics, Policy, Practice

pdf verion: The Sentinel_ week ending 13 September 2014

blog edition: comprised of the 35+ entries below posted on 14 September 2014

Editorial: WHO for the 21st Century – Margaret Chan

Editorial
WHO for the 21st Century
Margaret Chan
Margaret Chan is Director General of the World Health Organization, CH1211 Geneva 27, Switzerland.
Science Translational Medicine; 10 September 2014 vol 6, issue 253
http://stm.sciencemag.org/content/current

Next year, 2015, will be pivotal for global health. The deadline for reaching the United Nations Millennium Development Goals (MDGs) expires, and the MDGs will be succeeded by a new framework that focuses on poverty reduction and sustainable development (1). In the lead-up to 2015, the spotlight is already on the achievements and disappointments of the MDG era. Among the successes, 2 billion people have gained access to improved sanitation since 1990. Yet, there are still 2.5 billion people worldwide who do not have day-to-day use of functioning toilets. The death rate of children under 5 years has been cut by about one-half, and the rates of decline in child mortality in some African countries, notably Senegal and Rwanda, are among the fastest ever recorded. Nevertheless, between 6 million and 7 million children died in 2012, nearly half of whom died in the first month of life (2). The great majority of these deaths could have been prevented. During this period of reflection on the MDGs, we are also looking to the future. Our attention at the World Health Organization (WHO) is focused on ways to build on the global health successes of the past 25 years, on how to fill in the gaps, and on how we can continue to improve health in the post-2015 era.

Any allusion to our current place in the 21st century brings to mind events that take place over decades. Such events include the long-running epidemiological transition from communicable to noncommunicable diseases in our aging populations, now mostly located in cities, and the long-term health impacts of climate change and environmental degradation. But we must also contend with major events that take place on shorter time scales. The MDG era has coincided with, and is partly a product of, the huge increase in development (financial) assistance for health. This is reflected in the proliferation of health donors, global funds and partnerships, nongovernmental and civil society organizations, philanthropists, and commercial investors. The MDG era has also coincided with the growing wealth and more assertive voices of formerly low-income countries,

Symbolized by the BRIC nations (Brazil, Russia, India, China), and other countries such as Indonesia, Nigeria, and Thailand that have moved from low to middle income. As these events have unfolded, the reach of health has extended far beyond clinical practice and epidemiology. In the midst of debates about the changing role of international aid—and with the emergence of SARS, pandemic influenza, and most recently the Ebola virus—global health has become central to foreign policy and international relations.

In this time of transition, I will highlight some of the challenges we face in putting health at the heart of sustainable development. In confronting these challenges, we can draw on 66 years of WHO experience, but we are also prepared to work in new ways (3). As the post-2015 agenda is being crafted through international debate, our most important message is that good health is a valuable goal in its own right, and indispensable to poverty reduction and sustainable development. This is a global message with a human face: People want assurance that they have access to the health services they need and at a price they can afford. This is the essence and the promise of universal health coverage (4).

WHO is often referred to as a technical agency. We are certainly that—in our use of science and technology to underpin health policy. But WHO has a bigger role, in showing how technical approaches to health promotion and disease control are part of a larger vision for health and well-being, one in which good health for everyone is integral to social cohesion and stability.

The first of our challenges is to help reach, and surpass, the health targets set in the MDG era. One urgent task is to tackle the persistent causes of maternal and neonatal mortality. From a technical standpoint, we know how to do this, but we must find the right approach in each and every setting. Most maternal and child deaths can be prevented with high-quality care during pregnancy, delivery of babies by skilled birth attendants, breastfeeding, and through guaranteed access to appropriate antibiotics and immunization. Another well-defined task is to expand the coverage of antiretroviral therapy for HIV-positive people and to ensure prompt diagnosis and treatment for people with malaria, tuberculosis, and hepatitis. During the MDG era, disease control programs rightly emphasized the provision of good health services. But there are some extra steps to be taken—for example, to ensure that people who live under the threat of communicable diseases are adequately protected from financial risk, a vital ingredient of universal health coverage. Furthermore, our commitments to communicable disease control include elimination and eradication of, for example, malaria from selected countries, including Mexico, Malaysia, and South Africa, and polio and guinea worm disease from all countries.

The growing importance of noncommunicable diseases such as heart disease, diabetes, and cancer is, in part, the inevitable consequence of successfully controlling infections. In 2012, the average life expectancy at birth worldwide had increased to 70 years. This astonishing fact means that a large number of people now live long enough to suffer and eventually die from chronic illnesses—mainly cardiovascular disease and cancer. Clearly, we must all die of something, but many deaths from noncommunicable diseases are premature and preventable. Having examined the underlying causes and possible remedies, WHO’s World Health Assembly set a target of reducing premature mortality due to cardiovascular disease, cancer, diabetes, or chronic respiratory disease by 25% between 2010 and 2025.

To achieve this goal, WHO, as an intergovernmental organization, is using all available instruments at its disposal. The 2005 Framework Convention on Tobacco Control was the first global health treaty negotiated under the auspices of WHO. In 2013, with 178 signatories, an estimated 2.3 billion people were protected by at least one measure reducing tobacco demand that had been fully implemented by governments worldwide. The entire campaign against noncommunicable diseases was given a huge boost by the 2011 United Nations General Assembly, which recognized chronic diseases to be a major challenge, not merely for health but also for development in the 21st century.

The task of controlling communicable and noncommunicable diseases inevitably focuses on specific causes or risk factors. These are aided and abetted by insidious, systemic causes of ill health in populations, among which social inequality is a prime example. Despite some arguments to the contrary, we still inhabit a very unequal world. The richest 1% of people own ~40% of the world’s assets, and less than 1% of all assets are owned by the poorest 50% of people. The result is that 1.2 billion people still live in extreme poverty. And there are some disturbing trends. Over the past two decades, income inequality has been growing on average within and among countries—a trend that drives health inequalities, too. Social inequality is a structural problem that requires many kinds of remedy, but universal health coverage can make a powerful contribution. The first point about universal health coverage is that it must be precisely that: universal. However, universal health coverage is not merely the quest to reach an arithmetic target, but also has the goal of demanding equal rights to health and social protection for all, even those in the smallest minority.

The 1978 Alma Ata Declaration was one of the 20th century’s landmarks in public health. It emphasized the role of the state in providing adequate health and social measures. In the 21st century, states still have this responsibility of course, but now, health depends on many more actors. Recognizing that no intergovernmental organization can achieve its goals by operating from within the public sector alone, WHO now works with a multiplicity of nonstate actors—including nongovernmental organizations, philanthropic organizations, and academic institutions—to create and protect global public goods, such as standards of medical practice and the quality control of health products. WHO also works with nonstate actors to draw on private expertise, knowledge, commodities, personnel, and finances for the benefit of health and to encourage nonstate actors to improve their own activities to protect and promote health.

Last, nearly 30 years after the publication of a seminal report from the Rockefeller Foundation, we do still place a high premium on Good Health at Low Cost (5). Besides supporting research into better ways of sharing financial risks, and in addition to providing technical guidance for major funding initiatives (the Global Fund, the GAVI Alliance, and others), WHO is also promoting market mechanisms to lower the prices of high-quality commodities, including vaccines and essential medicines. Among the most successful efforts so far is “prequalification,” a mechanism that guarantees the quality of vaccines, drugs, and diagnostics for purchasing agencies, including the GAVI Alliance, and opens up the market to new manufacturers. In 2013, for example, prequalification of a Japanese encephalitis vaccine made in China cut the cost of each dose to US$0.30, well below the price of other Japanese encephalitis vaccines then on the market. This decision followed WHO approval, in 2011, of the China Food and Drug Administration as a functional regulatory authority for vaccines, a milestone on China’s road to becoming a global vaccine supplier.

In ventures of this kind, United Nations agencies often work best together, rather than alone. The 2013 report on Promoting Access to Medical Technologies and Innovation, prepared jointly by WHO, the World Intellectual Property Organization (WIPO), and the World Trade Organization (WTO), is a comprehensive guide to the interface between health, trade, and intellectual property. Likewise, the Pharmaceutical Manufacturing Plan for Africa, a proposal of the African Union Commission, is jointly supported by WHO, the Joint United Nations Programme on HIV and AIDS (UNAIDS), and the United Nations Industrial Development Organization (UNIDO).

As WHO moves into the post-2015 era of development, we shall remain true to our roots. We shall covetously guard our reputation for impartiality and sound science. We shall continue to serve as an honest broker, acting in the best interests of our Member States. We shall monitor health trends and track progress toward universal health coverage. We shall draw on our global perspective to help shape the agenda for health research. From guidelines to treaties, we shall use all of the instruments available to us in the cause of better health.

But, we are also open to new ways of doing business, by putting disease control programs in the context of universal health coverage, by actively seeking alliances beyond the public sector, and by promoting health, not only through health institutions, but also through agriculture, the economy, education, and the environment.

Everyone has a stake in health, and WHO has always worked to guard the health of everyone. But the professional business of health has changed profoundly since the turn of the millennium. WHO’s role, more than ever, is to provide leadership by building consensus around a shared responsibility for health, and by responding with agility to the unexpected challenges and new opportunities of the 21st century.

References
United Nations, Sustainable Development Knowledge Platform (United Nations, New York, 2014).
United Nations, The Millennium Development Goals Report 2013 (United Nations, New York, 2013).
World Health Organization, WHO Reforms for a Healthy Future. Report by the Director-General (World Health Organization, Geneva, 2012).
World Health Organization, The World Health Report 2013: Research for Universal Health Coverage (World Health Organization, Geneva, 2013).
S. Halstead, J. Walsh, K. Warren, Eds., Good Health at Low Cost (Rockefeller Foundation, Bellagio, Italy, 1985).

UN General Assembly Adopts Resolution Incorporating Sustainable Development Goals into Post-2015 Agenda

As Sixty-eighth Session Nears Conclusion, General Assembly Adopts Resolution Incorporating Sustainable Development Goals into Post-2015 Agenda
Delegates Also Pass Measures Addressing Malaria, Revitalizing Work of Assembly
United Nations
Sixty-eighth General Assembly GA/11544
Plenary
108th Meeting (PM)
10 September 2014

The General Assembly adopted three resolutions today, including one that would pave the way for the incorporation of sustainable development goals into the post-2015 development agenda.
In adopting the “Report of the Open Working Group on Sustainable Development Goals established pursuant to General Assembly resolution 66/288” (document A/68/L.61), as orally amended, the Assembly decided that the outcome document from the Open Working Group on Sustainable Development Goals would be the main basis for integrating the sustainable development goals into the future development agenda. The resolution went on to state that other inputs would also be considered during the intergovernmental negotiation process at the upcoming General Assembly session…

…In a final act, the Assembly adopted ”Consolidating gains and accelerating efforts to control and eliminate malaria in developing countries, particularly in Africa, by 2015” (document A/68/L.60), thereby calling for increased support for the implementation of international commitments and goals pertaining to the fight to eliminate malaria.

The resolution urged malaria-endemic countries to work towards financial sustainability to increase national resources allocated to controlling that disease, while also working with the private sector to improve access to quality medical services. Further, the resolution called upon Member States to establish or strengthen national policies, operational plans and research, with a view to achieving internationally agreed malaria targets for 2015…

…The General Assembly will reconvene on Thursday, 11 September, for a high-level stock-taking event on the Post-2015 Development Agenda.